Polaris Pharmaceuticals, Inc. (Polaris)

Oncology Corporate Profile

HQ Location

9373 Towne Centre Drive, Suite 150
San Diego, CA 92121

Company Description

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

Website: http://www.polarispharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ADI-PEG 20pegylated arginine deiminaseHepatocellular carcinoma (HCC)III
ADI-PEG 20pegylated arginine deiminaseLeukemiaII
ADI-PEG 20pegylated arginine deiminaseMelanomaII
ADI-PEG 20pegylated arginine deiminaseNon Small Cell Lung Cancer (NSCLC)II
ADI-PEG 20pegylated arginine deiminaseSmall Cell Lung Cancer (SCLC)II
ADI-PEG 20pegylated arginine deiminaseBreast cancerI
ADI-PEG 20pegylated arginine deiminaseGastric cancerI
ADI-PEG 20 (+ cisplatin)pegylated arginine deiminaseMelanomaI
ADI-PEG 20pegylated arginine deiminaseNon-Hodgkin's Lymphoma (NHL)I
ADI-PEG 20pegylated arginine deiminasePediatric cancerI
ADI-PEG 20 (+ docetaxel)pegylated arginine deiminaseProstate cancerI
TNF-PEG 20pegylated tumor necrosisVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.polarispharma.com

Recent News Headlines

There are no news items to display